1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons

Craig Jones(Johns Hopkins University), Ashwin Sachdeva(University of Manchester), M. Murray(MRC Clinical Trials Unit at UCL), Nicholas D. James(Royal Marsden NHS Foundation Trust), Eugène McCloskey(Arthritis UK), Janet E. Brown(University of Sheffield), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Noel W. Clarke(The Christie NHS Foundation Trust), Louise Brown(North Manchester General Hospital), Peter Dutey‐Magni(MRC Clinical Trials Unit at UCL), L.R. Murphy(MRC Clinical Trials Unit at UCL), Mahesh Parmar(University College London)
Annals of Oncology
October 1, 2023
10.1016/j.annonc.2023.09.2718
Cited by 5

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k